NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors

Dose-escalation part of study met primary objective

Study shows NP137 to have excellent safety and tolerability profile

Preliminary efficacy seen during dose-escalation phase in uterine cancers


Lyon, France – 12 December 2018

NETRIS Pharma, a clinical-stage company developing novel anticancer therapies targeting dependence receptors, announced today successful completion of the first-in-human study on the effects of netrin-1 inhibition in patients with advanced solid tumors. The Phase 1 dose-escalation study showed that NP137, a first-in-class monoclonal anti-netrin-1 blocking antibody, was safe and well tolerated up to 20mg/kg, with no dose limiting toxicity (DLT), meeting the primary objective. In addition, patients with advanced uterine cancers exhibited encouraging signs of anti-tumor activity, including prolonged stable disease and objective response.